SKYSTAR BIO-PHARMACEUTICAL COMPANY  

(Public, NASDAQ:SKBI)   Watch this stock  
Find more results for SKBI
1.21
-0.04 (-3.02%)
Real-time:   2:43PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.21 - 1.25
52 week 1.00 - 2.50
Open 1.25
Vol / Avg. 1,600.00/7,216.00
Mkt cap 9.22M
P/E 1.01
Div/yield     -
EPS 1.20
Shares 7.60M
Beta 0.76
Inst. own 4%
Aug 16, 2013
Q1 2013 SKYSTAR BIO-PHARMACEUTICAL COMPANY Earnings Conference Call - 7:45AM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin 30.57% 25.87%
Operating margin 40.76% 28.89%
EBITD margin - 32.43%
Return on average assets 9.49% 14.75%
Return on average equity 11.54% 17.12%
Employees 320 -
Carbon Disclosure Rating - -

Address

4/F, Building B, Chuangye Square No.48 Keji Road Gaoxin District
XI'AN, SXI 710065
China
+86-29-88193188 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

Skystar Bio-Pharmaceutical Company (Skystar) is a holding company. The Company is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products. It has four product lines: micro-organism products line, which include over 16 products; veterinary medicine line for poultry and livestock, which includes over 245 products; feed additives line, which includes over 16 products, and bio-pharmaceutical veterinary vaccine line, which includes over 10 products. All of the Company�s operations are carried out by Xi�an Tianxing Bio-Pharmaceutical Co., Limited (Xi�an Tianxing), a People�s Republic of China (PRC) joint stock company that the Company controls through contractual arrangements originally between Skystar Bio-Pharmaceutical (Cayman) Holdings Co., Ltd. (Skystar Cayman) and Xi�an Tianxing. As of December 31, 2011, it had over 3,846 customers in 29 provinces in China.

Officers and directors

Weibing Lu Chairman of the Board, Chief Executive Officer
Age: 49
Bio & Compensation  - Reuters
Bing Mei Chief Financial Officer
Age: 48
Bio & Compensation  - Reuters
Wei Wen Secretary, Director
Age: 44
Bio & Compensation  - Reuters
R. Scott Cramer Director
Age: 48
Bio & Compensation  - Reuters
Mark D. Chen Independent Director
Age: 44
Bio & Compensation  - Reuters
Qiang Fan Independent Director
Age: 56
Bio & Compensation  - Reuters
Chengtun Qu Independent Director
Age: 46
Bio & Compensation  - Reuters
Weirong Shen Independent Director
Age: 46
Bio & Compensation  - Reuters